N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Sponsor: Takeda • ClinicalTrials.gov ID: NCT07286058

Registry updated: 2026-09-09
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

Interventions

  • Zasocitinib (Drug)
    Zasocitinib oral tablets.

Eligibility criteria

Inclusion Criteria: 1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age. 2. The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies. 3. The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy. Exclusion Criteria: 1. Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study. 2. Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002). 3. The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia. 4. The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Conditions

Psoriatic Arthritis

Locations

  • Jeffrey Loomer, MD Arizona Arthritis & Rheumatology Research — Tucson, Arizona, United States
  • First OC Dermatology Research Inc. — Fountain Valley, California, United States
  • Purushotham & Akther Kotha MD — La Mesa, California, United States
  • Triwest Research Associates LLC — La Mesa, California, United States
  • The Cohen Medical Centers — Thousand Oaks, California, United States
  • Denver Arthritis Clinic - Lowry — Denver, Colorado, United States
  • Direct Helpers Research Center — Hialeah, Florida, United States
  • Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research — Hialeah, Florida, United States
  • IRIS Research and Development — Plantation, Florida, United States
  • Klein and Associates, M.D., P.A. — Hagerstown, Maryland, United States
  • Paramount Medical Research & Consulting, LLC — Middleburg Heights, Ohio, United States
  • West Tennessee Research Institute — Jackson, Tennessee, United States
  • Accurate Clinical Research — Baytown, Texas, United States
  • Novel Research LLC — Bellaire, Texas, United States
  • Novel Research | Abigail Neiman - Houston, TX — Houston, Texas, United States
  • Northwest Houston Arthritis Center — Houston, Texas, United States
  • West Texas Clinical Research — Lubbock, Texas, United States
  • Southwest Rheumatology Research, LLC — Mesquite, Texas, United States
  • Advanced Rheumatology of Houston — The Woodlands, Texas, United States
  • R.K. Will Pty Ltd — Victoria Park, Western Australia, Australia
  • The First Affiliated Hospital Of Bengbu Medical College — Bengbu, Anhui, China
  • Peking University Third Hospital — Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital — Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital — Guangzhou, Guangdong, China
  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST) — Wuhan, Hubei, China
  • Central South University - Xiangya School of Medicine - Zhuzhou Central Hospital — Zhuzhou, Hunan, China
  • The First Affiliated Hospital of Baotou Medical College — Baotou Shi, Inner Mongolia, China
  • Jiangxi Pingxiang People's Hospital — Pingxiang, Jiangxi, China
  • Linyi People's Hospital — Linyi Shi, Shandong, China
  • First Hospital of Shanxi Medical University — Taiyuan, Shanxi, China
  • West China Hospital of Sichuan University — Chengdu, Sichuan, China
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital — Chengdu, China
  • Clinical Hospital Center Rijeka - PPDS — Rijeka, Croatia
  • CCR Ostrava s.r.o. — Ostrava, Czechia
  • Pratia Czech s.r.o. — Pardubice, Czechia
  • Praglandia — Prague, Czechia
  • MEDICAL Plus s.r.o. — Uherské Hradiště, Czechia
  • Pv Medical Services — Zlín, Czechia
  • Innomedica OU — Tallinn, Estonia
  • North Estonia Medical Centre Foundation — Tallinn, Estonia
  • Clinical Research Centre Ltd — Tartu, Estonia
  • MediTrials OÜ — Tartu, Estonia
  • Hamburger Rheuma Forschungszentrum (HRF II) II — Hamburg, Germany
  • Vital Medical Center — Veszprém, Hungary
  • Galilee Medical Center — Nahariya, Israel
  • Kojunkai Social Medical Corporation Daido Clinic — Minami-ku, Nagoya-shi, Aichi-ken, Japan
  • Nagoya City University Hospital — Nagoya, Aichi-ken, Japan
  • Fukuoka University Hospital — Fukuoka, Hukuoka, Japan
  • Mie University Hospital — Tsu, Mie, Mie-ken, Japan
  • Sasebo Chuo Hospital — Sasebo-shi, Nagasaki, Japan
  • Nippon Life Hospital — Osaka, Osaka, Japan
  • St. Luke's International Hospital — Chuo-ku, Tokyo, Japan
  • National Hospital Organization Tokyo Medical Center — Meguro-Ku, Tokyo, Japan
  • Kyorin University Hospital — Mitaka-shi, Tokyo-To, Japan
  • Orto klīnika — Riga, Latvia
  • CGM Research Trust — Christchurch Central, New Zealand
  • Porter Rheumatology Ltd — Nelson, New Zealand
  • INTER CLINIC Piotr Adrian Klimiuk — Bialystok, Poland
  • Zdrowie Osteo Medic sc L i A Racewicz, A i J Supronik — Bialystok, Poland
  • Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty — Bialystok, Poland
  • NZOZ BIF-MED S.C. Arkadiusz Wawiernia, Mariola Roykiewicz, Rafal Roykiewicz — Bytom, Poland
  • Pratia MCM Krakow — Krakow, Poland
  • Twoja Przychodnia - Nowosolskie Centrum Medyczne sp. z o.o — Nowa Sól, Poland
  • Twoja Przychodnia Opolskie Centrum Medyczne — Opole, Poland
  • Pratia Poznań — Poznan, Poland
  • Twoja Przychodnia - Poznanskie Centrum Medyczne Sp. z o.o. — Poznan, Poland
  • Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj — Poznan, Poland
  • RCMed Oddzial Sochaczew — Sochaczew, Poland
  • MICS Centrum Medyczne Torun — Torun, Poland
  • Rheuma Medicus Sp. z o.o. — Warsaw, Poland
  • MTZ Clinical Research Powered by PRATIA - PPDS — Warsaw, Poland
  • Centrum Medyczne Reuma Park — Warsaw, Poland
  • ETG Warszawa Sp. z o.o. — Warsaw, Poland
  • FutureMeds Wroclaw — Wroclaw, Poland
  • Centro Reumatologico de Caguas — Caguas, Puerto Rico
  • GCM Medical Group, PSC — San Juan, Puerto Rico
  • Hospital Universitario Marques de Valdecilla — Santander, Cantabria, Spain
  • Clinical Trial Center of Chung Shan Medical University Hospital — Taichung, Taiwan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record